Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Ultra-Fast Test Screens for All Types of Cancer with Simple Blood Draw

By LabMedica International staff writers
Posted on 29 Aug 2024

Cancer can occur at any stage of life, irrespective of age, lifestyle, or genetic background, making early detection critical for effective treatment and better patient outcomes. More...

This underscores a pressing need for improved diagnostic methods in the medical field. Current cancer detection methods face challenges such as limited availability of screening tests, lengthy result processing times, high costs, and invasive procedures. Now, a pioneering technology has been developed that facilitates the early detection of cancer, potentially as early as stage -1, and aids in guiding subsequent imaging tests.

Oncosure (Pompano Beach, FL, USA) has launched its innovative Rapid Cancer Screening Test, democratizing access to early cancer detection. This test, requiring only a single blood draw, is capable of screening for all cancer types, thereby providing reassurance to individuals. Oncosure's cutting-edge screening technology employs rapid in situ hybridization and DNA fluorescent probes to deliver comprehensive and accurate cancer screening. The technology combines a rapid SITU hybridization platform, DNA fluorescent probes for ploidy detection, and cost-effective density gradient and low sequential centrifugation methods to provide thorough screening for aneuploidy across all chromosomes.

The Oncosure test identifies oncosomes—tiny vesicles that are markers of cancer cells—across all types of cancer. Employing advanced fluorescent microscopy, the test ensures precise and actionable outcomes. It offers a swift and dependable method for detecting cancer at very early stages, even stage -1, providing results that are both fast and definitive within a few hours. This enables healthcare providers to make timely decisions. Additionally, the Oncosure test can be instrumental in monitoring the efficacy of ongoing cancer treatments and in providing early detection of cancer recurrence for those in remission, enhancing the chances for successful intervention.

"One blood draw, all cancers—this is the future of cancer screening," said Jason Andrews, Vice President of Oncosure. "Cancer doesn't wait for symptoms, and neither should you. Our test empowers everyone to screen for any type of cancer with a single, non-invasive test."

Related Links:
Oncosure


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Real-Time PCR System
Gentier 96T
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.